|1.||Waters, Susanna: 6 articles (11/2014 - 09/2010)|
|2.||Waters, Nicholas: 5 articles (11/2014 - 09/2010)|
|3.||Ponten, Henrik: 5 articles (11/2014 - 10/2010)|
|4.||Squitieri, Ferdinando: 4 articles (11/2015 - 12/2011)|
|5.||Tedroff, Joakim: 4 articles (01/2013 - 09/2010)|
|6.||de Yebenes, Justo Garcia: 3 articles (01/2015 - 12/2011)|
|7.||Reilmann, Ralf: 3 articles (09/2013 - 12/2011)|
|8.||Kullingsjö, Johan: 3 articles (01/2013 - 10/2010)|
|9.||Sonesson, Clas: 3 articles (01/2013 - 09/2010)|
|10.||Klamer, Daniel: 2 articles (11/2014 - 01/2014)|
|1.||Huntington Disease (Huntington's Disease)
12/01/2011 - "We undertook a 6 month, randomised, double-blind, placebo-controlled trial to assess the efficacy of pridopidine in the treatment of motor deficits in patients with Huntington's disease. "
01/01/2014 - "The efficacy of the dopaminergic stabilizer, pridopidine, in reducing the voluntary and involuntary motor symptoms of Huntington's disease (HD) is under clinical evaluation. "
09/01/2013 - "A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease."
03/19/2013 - "This study provides Class IV evidence that pridopidine (≤90 mg/day) is generally safe and well-tolerated in patients with Huntington disease for up to 1 year."
12/01/2011 - "This study did not provide evidence of efficacy as measured by the mMS, but a potential effect of pridopidine on the motor phenotype of Huntington's disease merits further investigation. "
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
|3.||AIDS-Related Complex (ARC)
11/01/2014 - "In conclusion, the concurrent increase in cortical and striatal Arc expression induced by pridopidine and ordopidine appears unique for the dopaminergic stabilizers, as it was not shared by the reference compounds tested. "
11/01/2014 - "Pridopidine and ordopidine induced significant increases in cortical Arc expression, reaching 2.2- and 1.7-fold levels relative to control, respectively. "
11/01/2014 - "To further understand the neuropharmacological effects of pridopidine and ordopidine, and how they differ from other dopaminergic compounds in vivo, we assessed the expression of activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc), an immediate early gene marker associated with synaptic activation, in the frontal cortex and striatum. "
11/01/2014 - "The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression."
11/01/2014 - "The increase in cortical Arc expression is hypothesized to reflect enhanced N-methyl-D-aspartic acid receptor-mediated signalling in the frontal cortex, which could contribute to the state-dependent locomotor effects of pridopidine and ordopidine. "
|4.||Parkinson Disease (Parkinson's Disease)
|5.||Chorea (Rheumatic Chorea)
|3.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|7.||Messenger RNA (mRNA)
|8.||Levodopa (L Dopa)